Reported Earlier, Retension Pharmaceuticals Prices Upsized Initial Public Offering Of 3.75M Shares At $12.00 Each For $45.0M Gross Proceeds To Fund RTN-001 Phase 2b And Phase 3 Hypertension Trials

Loading news article.

Reported Earlier, Retension Pharmaceuticals Prices Upsized Initial Public Offering Of 3.75M Shares At $12.00 Each For $45.0M Gross Proceeds To Fund RTN-001 Phase 2b And Phase 3 Hypertension Trials | WAPE

Reported Earlier, Retension Pharmaceuticals Prices Upsized Initial Public Offering Of 3.75M Shares At $12.00 Each For $45.0M Gross Proceeds To Fund RTN-001 Phase 2b And Phase 3 Hypertension Trials

Article summary

Related companies

Analyzed by WAPE AI.

Comments —